广生堂：创新药GST-HG141III期临床试验进展顺利，已于7月25日完成首例受试者入组给药

Group 1 - The company has successfully progressed in the Phase III clinical trial of its innovative drug GST-HG141, with the first subject enrolled and dosed on July 25, 2025 [2] - The company will fulfill its information disclosure obligations in accordance with relevant regulatory requirements regarding subsequent clinical progress [2]